157 related articles for article (PubMed ID: 35428548)
1. Tubarial salivary gland sparing with proton therapy.
Wright CM; Lee DY; Kim M; Barsky AR; Teo BK; Lukens JN; Swisher-McClure S; Lin A
Med Dosim; 2022 Autumn; 47(3):222-226. PubMed ID: 35428548
[TBL] [Abstract][Full Text] [Related]
2. Tubarial gland sparing with intensity modulated radiation therapy for oropharyngeal cancers: A pilot study of dosimetric feasibility.
Yarlagadda S; McAllister N; Rzepczynski AE; Kutuk T; Kalman NS
Head Neck; 2024 Jul; 46(7):1582-1588. PubMed ID: 38747190
[TBL] [Abstract][Full Text] [Related]
3. Impact of salivary gland dosimetry on post-IMRT recovery of saliva output and xerostomia grade for head-and-neck cancer patients treated with or without contralateral submandibular gland sparing: a longitudinal study.
Wang ZH; Yan C; Zhang ZY; Zhang CP; Hu HS; Tu WY; Kirwan J; Mendenhall WM
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1479-87. PubMed ID: 20934262
[TBL] [Abstract][Full Text] [Related]
4. Salivary gland sparing and improved target irradiation by conformal and intensity modulated irradiation of head and neck cancer.
Eisbruch A; Ship JA; Dawson LA; Kim HM; Bradford CR; Terrell JE; Chepeha DB; Teknos TN; Hogikyan ND; Anzai Y; Marsh LH; Ten Haken RK; Wolf GT
World J Surg; 2003 Jul; 27(7):832-7. PubMed ID: 14509515
[TBL] [Abstract][Full Text] [Related]
5. Intensity-modulated radiotherapy or volumetric-modulated arc therapy in patients with head and neck cancer: Focus on salivary glands dosimetry.
Vallard A; Guy JB; Mengue Ndong S; Vial N; Rivoirard R; Auberdiac P; Méry B; Langrand-Escure J; Espenel S; Moncharmont C; Ben Mrad M; Diao P; Goyet D; Magné N
Head Neck; 2016 Jul; 38(7):1028-34. PubMed ID: 26855006
[TBL] [Abstract][Full Text] [Related]
6. Dosimetric Results for Adjuvant Proton Radiation Therapy of HPV-Associated Oropharynx Cancer.
Wright CM; Baron J; Lee DY; Kim M; Barsky AR; Teo BK; Lukens JN; Swisher-McClure S; Lin A
Int J Part Ther; 2022; 8(4):47-54. PubMed ID: 35530184
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of salivary gland function after treatment of head-and-neck tumors with intensity-modulated radiotherapy by quantitative pertechnetate scintigraphy.
Münter MW; Karger CP; Hoffner SG; Hof H; Thilmann C; Rudat V; Nill S; Wannenmacher M; Debus J
Int J Radiat Oncol Biol Phys; 2004 Jan; 58(1):175-84. PubMed ID: 14697436
[TBL] [Abstract][Full Text] [Related]
8. Using a reduced spot size for intensity-modulated proton therapy potentially improves salivary gland-sparing in oropharyngeal cancer.
van de Water TA; Lomax AJ; Bijl HP; Schilstra C; Hug EB; Langendijk JA
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):e313-9. PubMed ID: 21708427
[TBL] [Abstract][Full Text] [Related]
9. Intensity-modulated radiotherapy: is xerostomia still prevalent?
Chambers MS; Garden AS; Rosenthal D; Ahamad A; Schwartz DL; Blanco AI; Chao KS; Morrison WH; Ang KK; Weber RS
Curr Oncol Rep; 2005 Mar; 7(2):131-6. PubMed ID: 15717947
[TBL] [Abstract][Full Text] [Related]
10. Toxicity Profiles and Survival Outcomes Among Patients With Nonmetastatic Oropharyngeal Carcinoma Treated With Intensity-Modulated Proton Therapy vs Intensity-Modulated Radiation Therapy.
Youssef I; Yoon J; Mohamed N; Zakeri K; Press RH; Chen L; Gelblum DY; McBride SM; Tsai CJ; Riaz N; Yu Y; Cohen MA; Dunn LA; Ho AL; Wong RJ; Michel LS; Boyle JO; Singh B; Kriplani A; Ganly I; Sherman EJ; Pfister DG; Fetten J; Lee NY
JAMA Netw Open; 2022 Nov; 5(11):e2241538. PubMed ID: 36367724
[TBL] [Abstract][Full Text] [Related]
11. Submandibular gland-sparing radiation therapy for locally advanced oropharyngeal squamous cell carcinoma: patterns of failure and xerostomia outcomes.
Gensheimer MF; Liao JJ; Garden AS; Laramore GE; Parvathaneni U
Radiat Oncol; 2014 Nov; 9():255. PubMed ID: 25424729
[TBL] [Abstract][Full Text] [Related]
12. A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: initial results.
Chao KS; Deasy JO; Markman J; Haynie J; Perez CA; Purdy JA; Low DA
Int J Radiat Oncol Biol Phys; 2001 Mar; 49(4):907-16. PubMed ID: 11240231
[TBL] [Abstract][Full Text] [Related]
13. Proton beam radiation therapy results in significantly reduced toxicity compared with intensity-modulated radiation therapy for head and neck tumors that require ipsilateral radiation.
Romesser PB; Cahlon O; Scher E; Zhou Y; Berry SL; Rybkin A; Sine KM; Tang S; Sherman EJ; Wong R; Lee NY
Radiother Oncol; 2016 Feb; 118(2):286-92. PubMed ID: 26867969
[TBL] [Abstract][Full Text] [Related]
14. Salivary gland-sparing other than parotid-sparing in definitive head-and-neck intensity-modulated radiotherapy does not seem to jeopardize local control.
Chajon E; Lafond C; Louvel G; Castelli J; Williaume D; Henry O; Jégoux F; Vauléon E; Manens JP; Le Prisé E; de Crevoisier R
Radiat Oncol; 2013 May; 8():132. PubMed ID: 23721062
[TBL] [Abstract][Full Text] [Related]
15. Dosimetric comparison of three different involved nodal irradiation techniques for stage II Hodgkin's lymphoma patients: conventional radiotherapy, intensity-modulated radiotherapy, and three-dimensional proton radiotherapy.
Chera BS; Rodriguez C; Morris CG; Louis D; Yeung D; Li Z; Mendenhall NP
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1173-80. PubMed ID: 19386423
[TBL] [Abstract][Full Text] [Related]
16. The tubarial salivary glands: A potential new organ at risk for radiotherapy.
Valstar MH; de Bakker BS; Steenbakkers RJHM; de Jong KH; Smit LA; Klein Nulent TJW; van Es RJJ; Hofland I; de Keizer B; Jasperse B; Balm AJM; van der Schaaf A; Langendijk JA; Smeele LE; Vogel WV
Radiother Oncol; 2021 Jan; 154():292-298. PubMed ID: 32976871
[TBL] [Abstract][Full Text] [Related]
17. Proton FLASH Radiotherapy Ameliorates Radiation-induced Salivary Gland Dysfunction and Oral Mucositis and Increases Survival in a Mouse Model of Head and Neck Cancer.
Chowdhury P; Velalopoulou A; Verginadis II; Morcos G; Loo PE; Kim MM; Motlagh SAO; Shoniyozov K; Diffenderfer ES; Ocampo EA; Putt M; Assenmacher CA; Radaelli E; Lu J; Qin L; Liu H; Leli NM; Girdhani S; Denef N; Vander Stappen F; Cengel KA; Busch TM; Metz JM; Dong L; Lin A; Koumenis C
Mol Cancer Ther; 2024 Jun; 23(6):877-889. PubMed ID: 38593239
[TBL] [Abstract][Full Text] [Related]
18. Sparing all salivary glands with IMRT for head and neck cancer: Longitudinal study of patient-reported xerostomia and head-and-neck quality of life.
Hawkins PG; Lee JY; Mao Y; Li P; Green M; Worden FP; Swiecicki PL; Mierzwa ML; Spector ME; Schipper MJ; Eisbruch A
Radiother Oncol; 2018 Jan; 126(1):68-74. PubMed ID: 28823405
[TBL] [Abstract][Full Text] [Related]
19. Whole-Field Sequential Intensity-Modulated Radiotherapy for Local-Regional Advanced Head-and-Neck Squamous Cell Carcinoma.
Refaat T; Choi M; Thomas TO; Bacchus I; Agulnik M; Pelzer HJ; Mellott AL; Rademaker AW; Liu D; Sathiaseelan V; Mittal BB
Am J Clin Oncol; 2015 Dec; 38(6):588-94. PubMed ID: 24136140
[TBL] [Abstract][Full Text] [Related]
20. Accuracy requirements for head and neck intensity-modulated radiation therapy based on observed dose response of the major salivary glands.
Kapanen M; Collan J; Saarilahti K; Heikkonen J; Kairemo K; Tenhunen M
Radiother Oncol; 2009 Oct; 93(1):109-14. PubMed ID: 19435641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
